IL-13-PE

IL-13-PE is a recombinant fusion toxin protein therapy composed of human interleukin 13 (IL-13) fused to a truncated form of Pseudomonas aeruginosa exotoxin A (PE). It is designed as an immunotoxin that selectively targets cells expressing the interleukin 13 receptor alpha 2 (IL-13Rα2), which is overexpressed in certain tumors such as glioblastoma multiforme and adrenocortical carcinoma. Upon binding to the target receptor on tumor cells, the fusion protein is internalized; the PE moiety then inhibits protein synthesis within these cells by ADP-ribosylation of elongation factor 2, leading to cell death. The drug has been evaluated in clinical trials for brain tumors via convection-enhanced delivery and for metastatic adrenocortical carcinoma via intravenous infusion. While it demonstrated some disease stabilization and was generally well tolerated at lower doses, its efficacy was limited by neutralizing antibody formation and challenges with optimal drug delivery[1][5][6][8].

Other names

interleukin 13–Pseudomonas exotoxin A fusion proteinrecombinant cytotoxin consisting of human interleukin 13 and truncated Pseudomonas exotoxin A